Literature DB >> 26953211

Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Gaëlle Guiewi Makafe1, Yuanyuan Cao2, Yaoju Tan3, Mugweru Julius1, Zhiyong Liu1, Changwei Wang1, Moses M Njire1, Xingshan Cai3, Tianzhou Liu4, Bangxing Wang2, Wei Pang5, Shouyong Tan3, Buchang Zhang6, Wing Wai Yew7, Gyanu Lamichhane8, Jintao Guo1, Tianyu Zhang9.   

Abstract

We expressed the wild-type rplC and mutated rplC (Cys154Arg) genes, respectively, in Mycobacterium tuberculosis H37Ra and H37Rv in an attempt to delineate the role of rplC (Cys154Arg) regarding oxazolidinone resistance. An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26953211      PMCID： PMC4862453          DOI： 10.1128/AAC.00152-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Authors:  Patrick Beckert; Doris Hillemann; Thomas A Kohl; Jörn Kalinowski; Elvira Richter; Stefan Niemann; Silke Feuerriegel
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  E. coli ribosomal protein L4 is a feedback regulatory protein.

Authors:  J L Yates; M Nomura
Journal:  Cell       Date:  1980-09       Impact factor: 41.582

3.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

4.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Authors:  G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange
Journal:  Eur Respir J       Date:  2009-03-12       Impact factor: 16.671

6.  Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.

Authors:  Imran Ahmed; Kauser Jabeen; Raunaq Inayat; Rumina Hasan
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

7.  Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

Authors:  J C Rodríguez; L Cebrián; M López; M Ruiz; I Jiménez; G Royo
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

8.  Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.

Authors:  V Balasubramanian; S Solapure; H Iyer; A Ghosh; S Sharma; P Kaur; R Deepthi; V Subbulakshmi; V Ramya; V Ramachandran; M Balganesh; L Wright; D Melnick; S L Butler; V K Sambandamurthy
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

9.  Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.

Authors:  Tianyu Zhang; Si-Yang Li; Eric L Nuermberger
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

10.  Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.

Authors:  Robert S Wallis; Rodney Dawson; Sven O Friedrich; Amour Venter; Darcy Paige; Tong Zhu; Annette Silvia; Jason Gobey; Craig Ellery; Yao Zhang; Kathleen Eisenach; Paul Miller; Andreas H Diacon
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240
View more
  11 in total

1.  Combined Effect of the Cfr Methyltransferase and Ribosomal Protein L3 Mutations on Resistance to Ribosome-Targeting Antibiotics.

Authors:  Kevin K Pakula; Lykke H Hansen; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

3.  Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.

Authors:  Moses Njire; Na Wang; Bangxing Wang; Yaoju Tan; Xingshan Cai; Yanwen Liu; Julius Mugweru; Jintao Guo; H M Adnan Hameed; Shouyong Tan; Jianxiong Liu; Wing Wai Yew; Eric Nuermberger; Gyanu Lamichhane; Jinsong Liu; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors:  Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa.

Authors:  Sean Wasserman; Gail Louw; Limpho Ramangoaela; Garrick Barber; Cindy Hayes; Shaheed Vally Omar; Gary Maartens; Clifton Barry; Taeksun Song; Graeme Meintjes
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

6.  Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro.

Authors:  Minghao Hu; Lei Fu; Bin Wang; Jian Xu; Shaochen Guo; Jiaojie Zhao; Yuanyuan Li; Xiaoyou Chen; Yu Lu
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

Review 7.  Anti-tuberculosis drug resistance in Slovakia, 2018-2019: The first whole-genome epidemiological study.

Authors:  Matúš Dohál; Věra Dvořáková; Miluše Šperková; Igor Porvazník; Andrea Maurizio Cabibbe; Alberto Trovato; Andrea Spitaleri; Erik Michael Rasmussen; Kristián Pršo; Mária Škereňová; Daniela Maria Cirillo; Ivan Solovič; Juraj Mokrý
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-12-20

8.  In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.

Authors:  Matthew B McNeil; Devon D Dennison; Catherine D Shelton; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 9.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293

Review 10.  Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.

Authors:  Stephani L Stancil; Fuad Mirzayev; Susan M Abdel-Rahman
Journal:  Drug Des Devel Ther       Date:  2021-06-28       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.